NASDAQ · NBIX
Neurocrine Biosciences, Inc.
$146.38+$0.85 (+0.58%)
Neurocrine Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.35% below the high.
Loading market information…
NASDAQ · SUPN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Supernus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Supernus Pharmaceuticals, Inc.’s next earnings report is currently expected on Feb 23, 2027, with estimated earnings per share of $1.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Supernus Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Aug 5, 2025 | $0.91+93.62% vs estimate | $165.45M-1.65% vs estimate |
|---|
| Q1 2025 | May 6, 2025 | $0.42+10.53% vs estimate | $149.82M+1.28% vs estimate |
|---|
| Q4 2024 | Feb 25, 2025 | $0.75+63.04% vs estimate | $174.16M+12.18% vs estimate |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$146.38+$0.85 (+0.58%)
Neurocrine Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 21.35% below the high.
$207.83+$2.77 (+1.35%)
Jazz Pharmaceuticals plc’s quoted price sits in the upper half of its reported 52-week range, 21.98% below the high.
$288.62+$3.14 (+1.1%)
Praxis Precision Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.5% below the high.
$143.45-$0.06 (-0.04%)
Axsome Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.87% below the high.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$37.54+$1.20 (+3.3%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
$20.76+$0.44 (+2.17%)
Acadia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.95% below the high.
$19.32+$0.03 (+0.16%)
Denali Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
